JMB-HEADER NAUKA RAS RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 45(2011) N 6 p. 886-893;
E.Y. Tsareva1,2, O.G. Kulakova1,2, O.Y. Makarycheva1, A.N. Boiko5,2, S.G. Shchur5, N.Yu. Lashch2,5, N.F. Popova5,2, E.I. Gusev2, V.V. Bashinskaya2, D.V. Lvov3, A.V. Favorov3,4, M.F. Ochs4, O.O. Favorova1,2*

Pharmacogenomics of Multiple Sclerosis: Association of Immune Response Gene Polymorphisms with Copaxone Treatment Efficacy

1Russian Research-and-Production Center, Ministry of Health, Moscow, 121552 Russia
2Russian State Medical University, Moscow, 117437 Russia
3State Research Center GosNIIGenetika, Moscow, 117545 Russia
4Oncology Biostatistics and Bioinformatics, Johns Hopkins School of Medicine, Baltimore, 21205, USА
5Moscow City Multiple Sclerosis Center, 127018 Russia

*smedi@rambler.ru
Received - 2010-12-15; Accepted - 2011-01-31

A complex association analysis of copaxone (glatiramer acetate) immunotherapy efficacy with allelic polymorphism of the number of immune response genes, including the genes for interferon β (IFNB1), transforming growth factor β1 (TGFB1), interferon γ (IFNG), tumor necrosis factor (TNF), interferon α/β receptor 1 (IFNAR1), CC chemokine receptor 5 (CCR5), interleukin 7 receptor subunit α (IL7RA), cytotoxic T-lymphocyte antigen 4 (CTLA4), and HLA class II histocompatibility antigen β chain (DRB1), was performed using the APSampler algorithm for 285 multiple sclerosis patients of Russian ethnicity. The results demonstrate that the polymorphic variants of CCR5, DRB1, IFNG, TGFB1, IFNAR1, IL7RA, and, possibly, TNF and CTLA4 contribute to the copaxone treatment response. Single alleles of CCR5 and DRB1 genes were reliably associated with treatment efficacy. Allelic variants of the other genes exerted a weaker, though still reliable, effect on the copaxone treatment response, but as part of bi- and triallelic combinations only. The study may provide a basis for a prognostic test allowing an individual choice of immune-modulating treatment for a patient with multiple sclerosis.

pharmacogenomics, human, multiple sclerosis, copaxone, glatiramer acetate, Russians, autoimmune inflammation, cytokines, DNA, genes, SNP, PCR, APSampler



JMB-FOOTER RAS-JOURNALS